Senti Biosciences Holdings (SNTI) Net Equity Issued and Repurchased (2021 - 2025)

Senti Biosciences Holdings' Net Equity Issued and Repurchased history runs 4 years deep, the most recent figure standing at -$670000.0 for Q4 2025.

• In Q4 2025, Net Equity Issued and Repurchased changed N/A year-over-year to -$670000.0; the TTM figure through Dec 2025 stood at -$534000.0 (down 361.76% YoY), while the FY2023 annual figure was $512000.0, down 29.67% from the prior year.
• Net Equity Issued and Repurchased for Q4 2025 stood at -$670000.0, down from $136000.0 in the prior quarter.
• The five-year high for Net Equity Issued and Repurchased was $728000.0 in Q4 2022, with the low at -$67.0 million in Q4 2021.
• The 4-year median for Net Equity Issued and Repurchased is $136000.0 (2025), against an average of -$13.3 million.
• The sharpest annual moves came in 2022 and 2023: Net Equity Issued and Repurchased surged 101.09% in 2022, then slumped 71.98% in 2023.
• Senti Biosciences Holdings' Net Equity Issued and Repurchased stood at -$67.0 million in 2021, then surged by 101.09% to $728000.0 in 2022, then plunged by 71.98% to $204000.0 in 2023, then sank by 428.43% to -$670000.0 in 2025.
• Business Quant data shows SNTI's Net Equity Issued and Repurchased at -$670000.0 in Q4 2025, $136000.0 in Q3 2025, and $204000.0 in Q4 2023.